Federal Circuit Rules For Bristol-Myers In Repligen Patent Suit

Law360, New York (July 15, 2004, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has dealt biotech company Repligen a setback, ruling in favor of Bristol-Myers Squibb Co. in a dispute over the ownership of a patent for the immunosuppressant CTLA4-Ig.

The decision affirms a lower court’s ruling in favor of Bristol-Myers Squibb.

In August 2002, Repligen filed a patent lawsuit against Bristol-Myers Squibb in the U.S. District Court for the Eastern District of Michigan. Repligen said it is the exclusive licensee of all patent rights to CTLA4-Ig, which is owned...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.